AMG 224 / Amgen - LARVOL DELTA

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=42 | Completed | Sponsor: Amgen | Active, not recruiting ➔ Completed | Trial completion date: Sep 2023 ➔ Apr 2022

Trial completion • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1; N=41; Active, not recruiting; Sponsor: Amgen; Trial completion date: Mar 2022 ➔ Sep 2023

Clinical • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

"Moooorning, dearest Biiotwitter Because we always go back to our first love♥ $AMGN Ph1 study of AMG-224 (aBCMA) in R/R MM n=42 ORR: 23% mDoR: 14.7m https://t.co/VJAY3ZeNkn" (@BursatilBiotech)

"Belantamab: after median F/U of 6.3 to 6.9 months, median duration of response not reached. AMG224: In dose escalation cohort, the median duraation of response was 14.7 (4.1 - 29.8) months" (@Transplant_Doc)

Letter phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. (PubMed, Leukemia) - No abstract available

Clinical • Journal • P1 data • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1; N=41; Active, not recruiting; Sponsor: Amgen; Trial completion date: May 2020 ➔ Mar 2022

Clinical • Trial completion date